JP MORGAN/CALL/ELI LILLY & CO/960/0.01/17.01.25 | Market Closed - Börse Stuttgart 09:44:26 25/06/2024 BST | ||
| 0.64 EUR | +3.23% |
|
| 1 month | +60.00% | ||
| 3 months | +56.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 0.64 | +3.23% |
| 24/06/24 | 0.62 | 0.00% |
| 21/06/24 | 0.62 | -3.13% |
| 20/06/24 | 0.64 | -1.54% |
| 19/06/24 | 0.65 | +1.56% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 09:44 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK2EYG |
| ISIN | DE000JK2EYG1 |
| Date issued | 08/02/2024 |
| Strike | 960 $ |
| Maturity | 17/01/2025 (206 Days) |
| Parity | 100 : 1 |
| Emission price | 0.21 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.66 € |
|---|---|
| Lowest since issue | 0.21 € |
| Spread | 0.02 € |
| Spread % | 2.82% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6
USD
Average target price
860.5
USD
Spread / Average Target
-4.87%
- Stock Market
- Warrants
- Warrant
